EGFR (HER1) for Advanced Lung Cancer

Home / Clinical Studies / EGFR (HER1) for Advanced Lung Cancer

EGFR (HER1) for Advanced Lung Cancer

Chimeric Antigen Receptor T cell (CAR-T) therapy involves engineering cancer patients’ own immune cells to recognize and attack their tumors.  TRIAL DATA Phase I Clinical Trial – VIEW PRESS HERE September 28, 2015

Name of StudyTreatment of Chemotherapy Refractory EGFR(Epidermal Growth Factor Receptor) Positive Advanced Solid Tumors (CART-EGFR)
PhaseClinical Trial Phase I
ClinicalTrials.gov IdentifierNCT01869166 - view study online here
Study TypeInterventional
Study DesignEndpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Principal InvestigatorWei Dong Han, MD, PhD
Hospital(s)Chinese PLA General Hospital (PLAGH)